OBJECTIVE： To provide reference for rational use of secondary prevention drugs in patients with acute myocardial infarction. METHODS： The use of the drugs， including antithrombotic drugs （aspirin and ADP receptor antagonist）， lipid-lowering drugs （statins）， neuroendocrine inhibitors （ACEI or ARB and β-blocker） were analyzed with the data taken from the discharged cases with acute myocardial infarction from Jan. 2013 to Jun. 2015. RESULTS： 516 cases were enrolled. The utilization rates of aspirin， ADP receptor antagonist， statins， ACEI/ARB and β-blocker were 100％， 100％， 100％， 66.4％ and 85.3％. The rates of reaching standard dose were 100％， 98.8％， 99.4％， 82.0％ and 64.8％. A total of 33 cases suffered from ADR. CONCLUSIONS： The use of antithrombotic drugs and lipid-lowering drugs are rational relatively in our hospital， but there is still a certain gap between clinical practice and guideline in the use of neuroendocrine inhibitors.